PRELUDE THERAPEUTICS INC

Ryan Holmes, Andrew Moore, Max Foroutan, Jake Karwoski, Alex Grego, Carly Bachner1 Neha Bhagawat, Corey Basch, Soham Maity, Chun Chen, Sarah B. Pawley, Vijay Devannah, Sina Rezazadeh, Ross Kuskovsky, Joseph Rager, Kenneth Ray, Kirsten Gallagher, Yue Zou, Koichi Ito, Diane Heiser, Sang Hyun Lee, Peggy Scherle , Andrew P. Combs, Andrew W. Buesking The post Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 dual payload as targeted therapeutics for acute myeloid leukemia  appeared first on Prelude Therapeutics.

Monisha Sivakumar, Sarah Pawley, Corey Basch, Jimin Park, Justin Kurian, Anthony Reichelderfer, Yue Zou, Kirsten Gallagher, Miles Cowart, Joy Cote, Alexander Grego, Jessica Burtell, Amy Crossan, Michael Hulse, Anjana Agarwal, Arpita Mondal, Chun Chen, Vijay Devannah, Sina Rezazadeh, Quincy Lewis, Patrick Wen, Ken Ray, Raul Leal, Daniel Porreca, Ganfeng Cao, Neha Bhagwat, Shanthi Ganesan, Stefan […] The post First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile  appeared first on Prelude Therapeutics.

Koichi Ito, PhD Senior Director, Biology and Pharmacology, Prelude Therapeutics Incorporated The post Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes With Precision Degrader-Antibody Conjugates (DACs) appeared first on Prelude Therapeutics.

Andrew W. Buesking, Sr. Director, Chemistry on behalf of the pDAC team  The post Discovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader payloads  appeared first on Prelude Therapeutics.

Norman Fultang1, Ashley Schwab1, Sharayu Chandratre1, Jake Karwoski1, Grace Davis1, Ian Johnson1, Neha Bhagwat1, Yue Zou1, Arpita Mondal1, Max Foroutan1, Min Wang1, Andrew Buesking1, Chun Chen1, Corey Basch1, Ryan Holmes1, Sang Hyun Lee1, Diane Heiser1, Andrew Combs1, Peggy Scherle1 The post Discovery of First-in-Class Calreticulin-targeted Degrader Antibody Conjugates Delivering a CDK9 Degrader Payload for the Treatment of CALR-mutated MPNs appeared first on Prelude Therapeutics.

Neha Bhagwat1, Duanya Liu2, Xiaowei Wu1, Alexander Grego1, Amy Crossan1, Andrew Moore1, Arpita Mondal1, Carly Bachner1, Dani Roth1, Diego Elrio, John Rose1, Joseph Rager1, Joy Cote1, Kirsten Gallagher1, Klare Bersch1, Miles Cowart1, Min Wang1, Natalie Kurtz1, Norman Fultang1, SharayuChandratre1, Song Mei1, Srijita Dhar1, Sushanta Ratna1, Stephanie Rodgers1, Yann Loret1, Yue Zou1, Sandy Geeganage1, Andrew Combs1, […] The post Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms appeared first on Prelude Therapeutics.

Sri Sahasranaman is Senior Vice President of Clinical Pharmacology at Prelude Therapeutics and is responsible for leading and overseeing clinical pharmacology and pharmacometrics strategies to facilitate clinical development of assets. Before joining Prelude, Sri built and scaled up the Global Clinical Pharmacology organization at BeiGene (now BeOne) for six years. Previously, Sri worked at Genentech, Novartis […] The post Sri Sahasranaman, Ph.D. appeared first on Prelude Therapeutics.

Wojciech Jurczak, Clementine Sarkozy, Katharine L. Lewis, Geoffrey Shouse, Eliza A. Hawkes, Won Seog Kim, Monica Tani, François Lemonnier, Sarit E. Assouline, Franck Morschhauser, Bruce D. Cheson, Catherine S. Diefenbach, Gareth P. Gregory, Talha Munir, Petra Langerbeins, Constantine S. Tam, Gerardo Musuraca, Craig A. Portell, Anastasios Stathis, Young Rok Do, Jennifer Xavier, Muhtarjan Osman, Siminder […] The post A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed / Refractory Lymphoid Malignancies: Updated Analysis  appeared first on Prelude Therapeutics.

Norman Fultang, Ashley Schwab, Sharayu Chandratre, Ian Johnson, Jake Karwoski, Neha Bhagwat, Arpita Mondal, Min Wang, Yue Zou, Andrew Buesking, Max Foroutan, Chun Chen, Corey Basch, Ryan Holmes, Sang Hyun Lee, Diane Heiser, Andrew Combs, Peggy Scherle The post Discovery of First-in-Class Precision Antibody Drug Conjugates Targeting Mutant Calreticulin For the Treatment of Myeloproliferative Neoplasms appeared first on Prelude Therapeutics.

Timothy A. Yap, MD, PhD; Martin E. Gutierrez, MD; Wade T. Iams, MD; Victor Moreno, MD, PhD; Tatiana Hernández Guerrero, MD, PhD; Guzmán Alonso, MD; Carlos A. Gomez‑Roca, MD; Sophie Postel‑Vinay, MD, PhD; Fabian Acker, MD; Anna R. Minchom, MB BCh, FRCP, MD(res); Natasha B. Leighl, MD, MMSc, FRCPC, FASCO; William F. Novotny, MD; Chris […] The post A Phase 2 Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and a SMARCA4 Mutation  appeared first on Prelude Therapeutics.